Ladenburg Thalmann analyst Aydin Huseynov downgrades Allarity Therapeutics (NASDAQ:ALLR) from Buy to Neutral.
Mesoblast Advances Toward Remestemcel-L Approval for Pediatric SR-aGVHD: FDA Meeting Update
Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the
